 |
CD40/CD80/CD86 modified autologous dendritic cell therapy |
|---|---|
| Trade Name | |
| Orphan Indication | Treatment Type 1 diabetes mellitus patients with residual beta cell function |
| USA Market Approval | USA |
| USA Designation Date | 2013-12-20 00:00:00 |
| Sponsor | DiaVacs, Inc.;410 Tower Drive;Edgewater, New Jersey, 07020 |
